|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 39/395 | (2006.01) |
| C07K 16/00 | (2006.01) | ||
| C07H 21/04 | (2006.01) | ||
| C07K 16/28 | (2006.01) |
| (11) | Number of the document | 2566517 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11778283.9 |
| Date of filing the European patent application | 2011-05-04 | |
| (97) | Date of publication of the European application | 2013-03-13 |
| (45) | Date of publication and mention of the grant of the patent | 2018-10-24 |
| (46) | Date of publication of the claims translation | 2019-01-10 |
| (86) | Number | PCT/US2011/035231 |
| Date | 2011-05-04 |
| (87) | Number | WO 2011/140249 |
| Date | 2011-11-10 |
| (30) | Number | Date | Country code |
| 331177 P | 2010-05-04 | US |
| (72) |
WONG, Justin, US
VASQUEZ, Maximiliano, US
|
| (73) |
Five Prime Therapeutics, Inc.,
111 Oyster Point Boulevard, South San Francisco, CA 94080,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antikūnai, surišantys CSF1R |
| ANTIBODIES THAT BIND CSF1R |
| Payment date | Validity (years) | Amount | |
| 2023-04-24 | 13 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-05-04 |